Type 2 diabetes
Conditions
Interventions
Repaglinide: 0.75-1.5 mg/day (can be increased up to 3 mg/day if necessary) for 24 weeks.
Sitagliptin: 50 mg/day (can be increased up to 100 mg/day if necessary) for 24 weeks.
Sponsors
Kawasaki Medical School Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes patients, attending the OPD of the Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical School Hospital, insufficienttly controlled (HbA1c(NGSP) less than 8.4%) with alimentary therapy or with alpha-glucosidase inhibitors.
Exclusion criteria
Exclusion criteria: 1) Type1 diabetes mellitus. 2) Patients with serious ketosis, diabetic coma, or pre-coma. 3) Patients with severe infection, before and after surgery, or severe injury. 4) Patients with pregnancy or lactating. 5) Patients with severe hepatic dysfunction. 6) Patients with renal impairment. 7) Patients treated with insulin. 8) Patients who has a history of adverse events with each drugs. 9) Patients who has a history of hypersensitivity to each drugs. 10) Patients who are judged unsuitable to participate the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c(NGSP) 1,5AG 8-iso-prostaglandin F2a | — |
Countries
Japan
Contacts
Public ContactMitsuru Hashiramoto
Kawasaki Medical School Hospital Division of Diabetes, Endocrinology and Metabolism
Outcome results
None listed